{"id":"W2904897913","doi":"10.1016/j.cgh.2018.11.062","title":"Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab","year":2018,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; Robarts Clinical Trials; University of Calgary","funders":"Canadian Institutes of Health Research; Eisai; Ferring; Canadian Association of Gastroenterology; UCB; Prometheus; Janssen Canada; Amgen Canada; GlaxoSmithKline Australia; Schering-Plough; AbbVie; Takeda Pharmaceutical Company; Shire; Merck; Pfizer","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Concomitant; Golimumab; Internal medicine; Infliximab; Gastroenterology; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004494465,0.0002253199,0.0008530815,0.0002284773,0.0001959417,0.0006300017,0.0002786676,0.0003818559,0.001211657],"category_scores_gemma":[0.001869334,0.0001558004,0.001075406,0.0003492704,0.0001882092,0.0004775533,0.0003333865,0.0008470789,0.0001575525],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002702013,"about_ca_system_score_gemma":0.000266323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005740607,"about_ca_topic_score_gemma":0.001521399,"domain_scores_codex":[0.9994809,0.0001367398,0.00006937661,0.0000872874,0.0001082609,0.0001174506],"domain_scores_gemma":[0.9984517,0.0003653535,0.0006984322,0.0001080418,0.00007458072,0.0003018313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02778175,0.0006026463,0.9101066,0.0002317553,0.00285107,0.0005910995,0.0001002432,0.0004266565,0.008429371,0.00008791072,0.0006021121,0.04818879],"study_design_scores_gemma":[0.000372017,0.002121372,0.9951583,0.00003988796,0.0006927482,0.0003953063,0.0000737964,0.0003082072,0.0002596076,0.00006530129,0.0005036535,0.000009748156],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966522,0.002212164,0.00005617422,0.0001458172,0.00003831001,0.000006378739,0.00008656957,0.000006956037,0.0007955272],"genre_scores_gemma":[0.9992766,0.0003084035,0.00004134153,0.00009064427,0.00002894442,0.000003284463,0.0001327143,0.000001602024,0.0001165526],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001211657,"threshold_uncertainty_score":0.004053354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01696896795019479,"score_gpt":0.278141515346838,"score_spread":0.2611725473966432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}